StockNews.com began coverage on shares of Trinity Biotech (NASDAQ:TRIB – Free Report) in a research report report published on Saturday morning. The brokerage issued a sell rating on the stock.
Trinity Biotech Trading Down 6.1 %
Shares of TRIB stock opened at $0.66 on Friday. The firm has a market capitalization of $12.00 million, a price-to-earnings ratio of -0.29 and a beta of 1.20. The business’s 50-day moving average price is $0.79 and its 200-day moving average price is $1.12. Trinity Biotech has a 12 month low of $0.63 and a 12 month high of $3.55.
Institutional Investors Weigh In On Trinity Biotech
A hedge fund recently raised its stake in Trinity Biotech stock. Hunter Associates Investment Management LLC lifted its holdings in shares of Trinity Biotech plc (NASDAQ:TRIB – Free Report) by 5.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 378,590 shares of the company’s stock after purchasing an additional 18,780 shares during the period. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 as of its most recent filing with the SEC. 78.97% of the stock is owned by institutional investors and hedge funds.
Trinity Biotech Company Profile
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Read More
- Five stocks we like better than Trinity Biotech
- Which Wall Street Analysts are the Most Accurate?
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- How to Invest in the Best Canadian Stocks
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- How to trade penny stocks: A step-by-step guide
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
